Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed

Alzheimer's and Dementia

Volumn 2, Issue 3, 2006, Pages 153-154

  Aisen, Paul S ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; HOMOTAURINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN ATROPHY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HIPPOCAMPUS; HUMAN; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 33744906292     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.03.009     Document Type: Editorial

References (9)

1. Aisen P.S. The development of anti-amyloid therapy for Alzheimer's disease. from secretase modulators to polymerisation inhibitors. CNS Drugs 19 (2005) 989-996
2. Leber P. Slowing the progression of Alzheimer disease. Methodologic issues. Alzheimer Dis Assoc Disord 11 Suppl 5 (1997) S10-S20
3. Gervais F., Chalifour R., Garceau D., Kong X., Laurin J., et al. Glycosaminoglycan mimetics. A therapeutic approach to cerebral amyloid angiopathy. 2001. Amyloid 8 Suppl 1 (2001) 28-35
4. Aisen P.S., Mehran M., Poole R., Lavoie I., Gervais F., et al. Clinical data on Alzhemed after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Neurobiol Aging 25 (2004) 20
5. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25 (2005) 10598-10606
6. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20 (2006) 6-15
7. Barten D.M., Guss V.L., Corsa J.A., Loo A.T., Hansel S.B., et al. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 312 (2004) 635-643
8. Best J.D., Jay M.T., Otu F., Churcher I., Reilly M., et al. In vivo characterisation of A{beta}(40) changes in brain and CSF using the novel {gamma}-secretase inhibitor MRK-560 (N-[cis-4-[(4-chlorophenyl)sulfonyl]-4- (2,5-difluorophenyl)cyclohexyl]-1,1,1- trifluoromethanesulfonamide) in the rat. J Pharmacol Exp Ther 317 (2006) 786-790
9. Lemere C.A., Beierschmitt A., Iglesias M., Spooner E.T., Bloom J.K., et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. 2004. Am J Pathol 165 (2004) 283-297